CSIMarket



Gilead Sciences Inc   (GILD)
Other Ticker:  
 
 


Gilead Sciences Inc Segments

 
Viread
   3.14 % of total Revenue
Truvada
   9.85 % of total Revenue
Emtriva
   4.26 % of total Revenue
HIV products Total
   24.47 % of total Revenue
AmBisome
   1.19 % of total Revenue
Other products
   2.56 % of total Revenue
Atripla
   9.07 % of total Revenue
Letairis
   2.04 % of total Revenue
Ranexa
   1.64 % of total Revenue
Complera Eviplera
   4.26 % of total Revenue
Stribild
   5.18 % of total Revenue
Sovaldi
   14.97 % of total Revenue
Harvoni
   41.84 % of total Revenue
 

Business Segments (June 30, 2015)
Revenues
(in millions $)
II. Quarter
%
(of total Revenues)
(June 30, 2015)
Income
(in millions $)
II. Quarter
%
(Profit Margin)
Viread
271.00 3.14 % 0.00 -
Truvada
849.00 9.85 % 0.00 -
Emtriva
367.00 4.26 % 0.00 -
HIV products Total
2,110.00 24.47 % 0.00 -
AmBisome
103.00 1.19 % 0.00 -
Other products
221.00 2.56 % 0.00 -
Atripla
782.00 9.07 % 0.00 -
Letairis
176.00 2.04 % 0.00 -
Ranexa
141.00 1.64 % 0.00 -
Complera Eviplera
367.00 4.26 % 0.00 -
Stribild
447.00 5.18 % 0.00 -
Sovaldi
1,291.00 14.97 % 0.00 -
Harvoni
3,608.00 41.84 % 0.00 -
Total
8,623.00 100 % 0.00 -

• View Income Statement • View Competition by Segment • View Annual Report

Growth rates by Segment (June 30, 2015)
Y/Y Revenue
%
II. Quarter
Q/Q Revenue
%
(June 30, 2015)
Y/Y Income
%
II. Quarter
Q/Q Income
%
Viread
3.94 % 15.81 % - -
Truvada
5.26 % 10.12 % - -
Emtriva
22.55 % - - -
HIV products Total
18.47 % 39.55 % - -
AmBisome
8.66 % 21.18 % - -
Other products
461.95 % 16.93 % - -
Atripla
-10.19 % 6.54 % - -
Letairis
21.62 % 16.56 % - -
Ranexa
15.62 % 20.51 % - -
Complera Eviplera
22.55 % 19.16 % - -
Stribild
65.85 % 25.56 % - -
Sovaldi
-62.91 % 32.82 % - -
Harvoni
- 0.81 % - -
Total
28.94 % 15.03 % - -

• View Growth rates • View Competitors Segment Growth • View Market Share

To get more information on Gilead Sciences Inc 's Viread, Truvada, Emtriva, HIV products Total, AmBisome, Other products, Atripla, Letairis, Ranexa, Complera Eviplera, Stribild, Sovaldi, Harvoni, Total segment. Select each division with the arrow.

  Gilead Sciences Inc 's

Business Segments Description



Our Products

HIV Products

· Viread is an oral formulation of a nucleotide analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat human immunodeficiency virus (HIV) infection in adults. We sell Viread in the United States through our U.S. commercial team and wholesalers, in the major European countries through our European commercial team and distributors, and in Japan through our corporate partner, Japan Tobacco. We have an exclusive, worldwide license to patent rights and related technology for Viread from the Institute of Organic Chemistry and Biochemistry (part of the Academy of Sciences of the Czech Republic) and Rega Stichting v.z.w. (together, IOCB/REGA).

· Emtriva is an oral formulation of a nucleoside analogue reverse transcriptase inhibitor, dosed once a day as part of a combination therapy to treat HIV infection in adults. We sell Emtriva in the United States through our U.S. commercial team and wholesalers and in the major European countries through our European commercial team and distributors. We have an exclusive, worldwide license to patent rights and related technology for Emtriva from Emory University.

· Truvada is an oral tablet dosed once a day as part of a combination therapy to treat HIV infection in adults. It is a fixed-dose combination of our anti-HIV medications Emtriva and Viread. Truvada combines 200 mg of emtricitabine (Emtriva) and 300 mg of tenofovir disoproxil fumarate (Viread). Truvada is currently sold in the United States through our U.S. commercial team and wholesalers. Our international commercial team began launching Truvada in the European Union following recent regulatory approval in February 2005. We have an exclusive, worldwide license to patent rights and related technology for the components of Truvada from IOCB/REGA and Emory University.

AmBisome

· AmBisome is a proprietary liposomal formulation of amphotericin B, a powerful antifungal agent to treat serious invasive fungal infections caused by various fungal species. By delivering amphotericin B in our proprietary liposomal formulation, AmBisome reduces the rate and severity of kidney toxicity and injection-related reactions associated with amphotericin B and allows patients to receive higher doses of amphotericin B. AmBisome is approved for sale in more than 45 countries, including the United States and the countries of the European Union. In more than 20 of the countries where AmBisome is approved, including the United States, we are authorized to promote AmBisome for empirical treatment of fungal infections, that is, treatment of patients where a strong suspicion, without definite confirmation, exists for a potentially life-threatening invasive fungal infection. In the remaining countries, AmBisome is approved for use either as first-line treatment of serious invasive fungal infection or as second-line treatment after conventional amphotericin B therapy fails or when conventional amphotericin B cannot be tolerated. We market AmBisome in the major countries of Europe and co-promote AmBisome in the United States with Fujisawa Healthcare, Inc. (Fujisawa).

Hepsera

· Hepsera is an oral formulation of a nucleotide analogue hepatitis B virus (HBV) DNA polymerase inhibitor, dosed once a day to treat chronic hepatitis B. Hepsera is approved for sale in the United States for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active liver disease. Our U.S. commercial team and wholesalers sell Hepsera in the United States. We sell Hepsera in the major European Union countries through our European commercial team and distributors. We have licensed the rights to commercialize Hepsera solely for the treatment of hepatitis B in China, Japan, Korea, Taiwan, the rest of Asia, Latin America and certain other territories to GlaxoSmithKline (GSK), which launched Hepsera in Japan, South Korea and Taiwan in 2004. We have an exclusive, worldwide license to patent rights and related technology for adefovir dipivoxil from IOCB/REGA.

Vistide

· Vistide is an antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. CMV retinitis is a condition characterized by lesions that form on a patient’s retina that affects persons with weakened immune systems and is most common in patients with AIDS. Vistide is approved for sale and is sold in the United States by our U.S. commercial team, and by Gilead’s ex-U.S. partner, Pfizer Inc. (Pfizer) (formerly Pharmacia Corporation), in 25 countries for the treatment of CMV retinitis in patients with AIDS.

DaunoXome

· DaunoXome is a liposomal formulation of the anticancer agent daunorubicin. It is approved for sale and has been sold in more than 20 countries for the treatment of AIDS-related Kaposi’s sarcoma. It is sold in the United States by our U.S. commercial team and by independent distributors abroad. In December  2003, we decided to discontinue selling this product; however, in 2004, we subsequently received unanticipated requests in Europe to reconsider selling DaunoXome. We are continuing to sell this product in a limited number of countries and are currently evaluating our supply and sales strategy with regard to this product.

Other Royalty Sources

· Macugen is an anti-angiogenic injection for the treatment of neovascular age-related macular degeneration (AMD). The drug is an inhibitor of vascular endothelial growth factor (VEGF), which is known to play a role in the development of certain ophthalmic diseases. Macugen was approved by the FDA in the United States in December 2004 and began selling in January 2005. The product is not yet approved outside the United States. Macugen was developed by Eyetech Pharmaceuticals, Inc. (Eyetech), using technology licensed from us. Eyetech holds the exclusive rights to manufacture and sell Macugen worldwide, subject to Eyetech’s obligation to pay us a percentage of the net revenues that Eyetech generates from Macugen sales. The patents to the technology we license to Eyetech expire in 2017 in the United States and Europe.

· Tamiflu is an oral pill for the treatment and prevention of influenza A and B. Tamiflu is in a class of prescription drugs called neuraminidase inhibitors. Tamiflu is approved in more than 60 countries, including the United States, Japan and the countries of the European Union for treatment of influenza in children and adults. Tamiflu is also approved in the United States and the European Union for the prevention of influenza in adolescents and adults. We developed Tamiflu with F. Hoffmann-LaRoche Ltd (Roche), and Roche has the exclusive right to manufacture and sell Tamiflu worldwide, subject to its obligation to pay us a percentage of the net revenues that Roche generates from Tamiflu sales, subject to reduction for certain defined manufacturing costs.

   

Sales by Geography Competition By Business Segments Company Profile
       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

DLPN's Profile

Stock Price

DLPN's Financials

Business Description

Fundamentals

Charts & Quotes

DLPN's News

Suppliers

DLPN's Competitors

Customers & Markets

Economic Indicators

DLPN's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071